Aniracetam is a derivative of piracetam which positively modulates AMPA receptors and has pro-cholinergic properties. Tentative evidence suggests that Aniracetam may be useful in the treatment anxiety and depression, but studies conducted in humans are lacking.
ANIRACETAM FACT SHEET[su_table]
|Originally developed by:||Roche Pharmaceuticals|
|Dose||400-1500mg (in divided doses)|
|Potency (compared to other racetams)||Medium (12-25mg/kg)|
|Comments||Improved psychometric parameters by up to 30% in a cohort with traumatic brain injury|